Glaxo Goes Head-to-Head on HPV

Source: Brian Orelli

"Data from a trial presented today seems to suggest that the vaccine performs better, but Glaxo may have used the wrong measurement to make a definitive conclusion. Instead of looking at the rate of infection with HPV in females, which is what the vaccine is actually preventing, Glaxo looked at antibody levels in the patients."

Maybe it’s the sports fanatic in me, but I love a good head-to-head clinical trial. In a trial against a placebo, a company can only hurt itself. But if a drug fails head-to-head against a rival, the company gets hurt, and its competitor gets a boost. It takes guts for a company to put itself on the line like that.

Then again, GlaxoSmithKline didn't have much of a choice. Merck's human papillomavirus (HPV) vaccine Gardasil was first to the U.S. market, and the easiest way for Glaxo's second-fiddle, Cervarix, to compete is to show that it works better than the top dog



Full story here

Read more about Glaxo's, Cervarix:

Teenage Girls Sue Over GSK's Cancer Jab, Cervarix!

Cervical Cancer, Ofsted & GlaxoSmithKline

GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine

HPV Vaccine Video on Youtube

Concerns over GSK's Cervarix vaccine

Cervarix - Promotion or Scaremongering?

UP YOURS GLAXO!

Mindy Merck & Gail Glaxo Dilemma

LOLA'S LAND PROMOTING HPV VACCINE

GlaxoSmithKline's Cervarix. Is Your Daughter Safe?

More debate on GSK's Cervarix

Fid


SEROXAT SUFFERERS STAND UP AND BE COUNTED

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING